Hyperglycaemia suppresses microrna expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus

Thrombosis and Haemostasis

Volumn 117, Issue 3, 2017, Pages 529-542

  Fejes, Zsolt ^a   Póliska, Szilárd ^a   Czimmerer, Zsolt ^a   Káplár, Miklós ^a   Penyige, András ^a,b   Gál Szabó, Gabriella ^a   Beke Debreceni, Ildikó ^a   Kunapuli, Satya P ^c   Kappelmayer, János ^a   Nagy, Béla ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Hyperglycaemia; Megakaryocyte; MicroRNA; Platelet activation

Indexed keywords

BETA3 INTEGRIN; DICER; FIBRINOGEN RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MICRORNA; MICRORNA 126; MICRORNA 140; MICRORNA 223; MICRORNA 26B; P2RY12 PROTEIN; PADGEM PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALPAIN; CALPEPTIN; CIRCULATING MICRORNA; CYSTEINE PROTEINASE INHIBITOR; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; DIPEPTIDE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y12 RECEPTOR; RIBONUCLEASE III; SELP PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; UPREGULATION; ANTAGONISTS AND INHIBITORS; BLOOD; DOWN REGULATION; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; GLUCOSE BLOOD LEVEL; K-562 CELL LINE; MEGAKARYOCYTE; METABOLISM; THROMBOCYTE; TIME FACTOR;

ADULT; BIOMARKERS; BLOOD GLUCOSE; BLOOD PLATELETS; CALPAIN; CASE-CONTROL STUDIES; CIRCULATING MICRORNA; CROSS-SECTIONAL STUDIES; CYSTEINE PROTEINASE INHIBITORS; DEAD-BOX RNA HELICASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOWN-REGULATION; FEMALE; HUMANS; K562 CELLS; MALE; MEGAKARYOCYTES; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; RECEPTORS, PURINERGIC P2Y12; RIBONUCLEASE III; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 85014244193     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-04-0322     Document Type: Article

References (50)

1. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-1291.
2. Nagy B Jr, Csongrádi E, Bhattoa HP, et al. Investigation of Thr715Pro P-selectin gene polymorphism and soluble P-selectin levels in type 2 diabetes mellitus. Thromb Haemost 2007; 98: 186-191.
3. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
4. Lemkes BA, Hermanides J, Devries JH, et al. Hyperglycaemia: a prothrombotic factor? J Thromb Haemost 2010; 8: 1663-1669.
5. Yngen M, Ostenson CG, Li N, et al. Acute hyperglycaemia increases soluble P-selectin in male patients with mild diabetes mellitus. Blood Coagul Fibrinolysis 2001; 12: 109-116.
6. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
7. Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21: 152-160.
8. Fadini GP, Ferraro F, Quaini F, et al. Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem Cells Transl Med 2014; 3: 949-957.
9. Olivieri F, Bonafè M, Spazzafumo L, et al. Age-and glycaemia-related miR-126-3p levels in plasma and endothelial cells. Aging 2014; 6: 771-787.
10. Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16: 961-966.
11. Rondina MT, Weyrich AS. Regulation of the genetic code in megakaryocytes and platelets. J Thromb Haemost 2015; 13 (Suppl 1): S26-32.
12. Pan Y, Liang H, Liu H, et al. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. J Immunol 2014; 192: 437-446.
13. Teruel-Montoya R, Kong X, Abraham S, et al. MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression. PLoS One 2014; 9: e102259.
14. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011; 117: 5189-5197.
15. Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008; 28: s17-24.
16. Liverani E, Kilpatrick LE, Tsygankov AY, et al. The role of P2Y12 receptor and activated platelets during inflammation. Curr Drug Targets 2014; 15: 720-728.
17. Matsuno H, Tokuda H, Ishisaki A, et al. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab 2005; 90: 920-927.
18. Sudic D, Razmara M, Forslund M, et al. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 2006; 133: 315-322.
19. Nagy B Jr, Jin J, Ashby B, et al. Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolaemia. J Thromb Haemost 2011; 9: 810-819.
20. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 8: 369-378.
21. Duan X, Zhan Q, Song B, et al. Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke. J Diabetes Complications 2014; 28: 705-710.
22. Elgheznawy A, Shi L, Hu J, et al. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res 2015; 117: 157-165.
23. Stenberg PE, McEver RP, Shuman MA, et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-886.
24. Kappelmayer J, Nagy B Jr, Miszti-Blasius K, et al. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 2004; 42: 475-486.
25. Plé H, Landry P, Benham A, et al. The repertoire and features of human platelet microRNAs. PLoS One 2012; 7: e50746.
26. Czimmerer Z, Hulvely J, Simandi Z, et al. A versatile method to design stemloop primer-based quantitative PCR assays for detecting small regulatory RNA molecules. PLoS One 2013; 8: e55168.
27. Westerweel PE, Teraa M, Rafii S, et al. Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus. PLoS One 2013; 8: e60357.
28. Duncan MT, Shin S, Wu JJ, et al. Dynamic transcription factor activity profiles reveal key regulatory interactions during megakaryocytic and erythroid differentiation. Biotechnol Bioeng 2014; 111: 2082-2094.
29. Dobiásová M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem 2004; 50: 1113-1115.
30. Csongrádi É, Nagy B Jr, Fülöp T, et al. Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. Thromb Haemost 2011; 106: 683-692.
31. Stratz C, Nührenberg TG, Binder H, et al. Micro-array profiling exhibits remarkable intra-individual stability of human platelet micro-RNA. Thromb Haemost 2012; 107: 634-641.
32. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
33. Kaudewitz D, Skroblin P, Bender LH, et al. Association of MicroRNAs and YRNAs With Platelet Function. Circ Res 2016; 118: 420-432.
34. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290-299.
35. Edelstein LC, McKenzie SE, Shaw C, et al. MicroRNAs in platelet production and activation. J Thromb Haemost 2013; 11 (Suppl 1): 340-350.
36. Pescador N, Pérez-Barba M, Ibarra JM, et al. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS One 2013; 8: e77251.
37. Leierseder S, Petzold T, Zhang L, et al. MiR-223 is dispensable for platelet production and function in mice. Thromb Haemost 2013; 110: 1207-1214.
38. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 2009; 32: 525-527.
39. Simon LM, Edelstein LC, Nagalla S, et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 2014; 123: e37-45.
40. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112: 595-600.
41. Stratz C, Nührenberg T, Fiebich BL, et al. Controlled type II diabetes mellitus has no major influence on platelet micro-RNA expression. Results from microarray profiling in a cohort of 60 patients. Thromb Haemost 2014; 111: 902-911.
42. Wang L, Erling P, Bengtsson AA, et al. Transcriptional down-regulation of the platelet ADP receptor P2Y(12) and clusterin in patients with systemic lupus erythematosus. J Thromb Haemost 2004; 2: 1436-1442.
43. Shi R, Zhou X, Ji WJ, et al. The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy. Biomed Res Int 2015; 2015: 981841.
44. Zhang YY, Zhou X, Ji WJ, et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis 2014; 38: 65-72.
45. Jones MR, Quinton LJ, Blahna MT, et al. Zcchc11-dependent uridylation of microRNA directs cytokine expression. Nat Cell Biol 2009; 11: 1157-1163.
46. Káplár M, Kappelmayer J, Veszprémi A, et al. The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets 2001; 12: 419-422.
47. Ye EA, Steinle JJ. miR-146a Attenuates Inflammatory Pathways Mediated by TLR4/NF-κB and TNFα to Protect Primary Human Retinal Microvascular Endothelial Cells Grown in High Glucose. Mediators Inflamm 2016; 2016: 3958453.
48. Xiang Y, Cheng J, Wang D, et al. Hyperglycaemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015; 125: 3377-3387.
49. Finn NA, Eapen D, Manocha P, et al. Coronary heart disease alters intercellular communication by modifying microparticle-mediated microRNA transport. FEBS Lett 2013; 587: 3456-3463.
50. Randriamboavonjy V, Isaak J, Elgheznawy A, et al. Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. Blood 2012; 120: 415-423.